Review on giant cell tumor of bone, with data on clinics, histopathology and genetics
A characteristic well-defined eccentric, lytic subchondral lesion involving the epiphysis and metaphysis. The borders are well defined and usually not sclerotic. Pathologic fracture is present in 5-10% of giant cell tumours.
Dynamic MRI shows a fast uptake and a slow wash out of contrast.
Classification
Giant cell tumor of bone is a locally aggressive primary bone neoplasm.
Clinics and pathology

Disease
Locally destructive, mono-ostotic tumoral lesion, typically presenting in the meta-epiphysis of long tubular bones with predilection for the knee region of skeletally mature patients (more than 95% of the patients is older than 25 years). Poly-ostotic lesions are exceptionally rare, counting for less than 1% of all cases. In these cases especially brown tumour of hyperparathyreoidism should be considered, which may look histologically identical. Although defined as a benign lesion, adjacent soft tissue invasion, angiovascular invasion and pulmonary metastases (1%) may occur.
Phenotype / cell stem origin
Primitive mesenchymal stromal cell.
Embryonic origin
Mesoderm.
Etiology
The exact origin is still unknown, but data obtained from ultrastructural analyses and cell cultures, as well as novel molecular data, suggest that the stromal cell, or mononuclear spindle cell, is neoplastic. The mononuclear rounded cells and the osteoclastic giant cells are seen as reactive. Therefore, some suggest that stromal cell tumour is a better name, because this fits more precisely the concept of the mononuclear spindled cell (stromal cell) as neoplastic.
Epidemiology
This tumour represents 8% of all primary and approximately 20% of benign primary bone tumours. Mostly affecting adults in the third, fourth and fifth decade of life (72%). It is very rarely seen under the age of 10 years (1,3%). There is a slight female predominance (male/female ratio: 46,6%/53,4%).
Clinics
Pain of several weeks to months duration and a constantly expanding mass on X-ray, primary in the epiphysis, leading to cortex destruction, pathological fracture and soft tissue invasion. Finally ulceration of the skin occurs if not threatened. A pathological fracture could occasionally be the first sign of this tumour. 
Treatment
Surgical intervention is the treatment of choice and therapeutic inhibition of osteoclast formation and activity with denosumab (RANK-RANKL inhibitor) provides another modality of treatment. Mostly a curettage followed by local adjuvant cryosurgery or phenol instillation is sufficient to eradicate this lesion and to save the joint. The use of polymethylmetacrylate for filling the cavity after curettage additively decreases the percentage of recurrences. An added advantage of using cement is that recurrences are detected sooner. Sometimes 'en bloc' resection is needed to be curative. Pulmonal metastases are treated by local excision.
Evolution
Non-treatment always leads to destruction of cortical bone, to soft tissue invasion and finally to ulceration of the skin. Local recurrences can occur following proper treatment, mostly indicating less radical initial resection.
Prognosis
Good, despite of recurrences and pulmonary metastases. In general much is depending on the surgical technique and expertise in combination with the histological grade of this tumour. Although pulmonary metastases may occur in rare cases, angiovascular invasion does not have any significant influence on its prognosis. The mortality rate due to giant cell tumour is about 4%.
Genetics
A specific driver mutation in the histone 3.3 gene H3F3A (p.Gly34) was recently identified in approximately 92% of giant cell tumours of bone. H3F3A mutation detection can be used as a diagnostic tool for the distinction of giant cell tumor of bone from other giant cell-containing tumors. A subset of the mutations can be easily detected using a G34W mutation specific antibody.
Cytogenetics
No recurrent chromosomal structural or numeric aberrations of importance have been detected yet.
When confronted with a rearrangement, especially concerning 16q22 or 17p3, an associated aneurysmal bone cyst should be excluded.
Cytogenetics Morphological
The most frequent chromosomal anomaly is telomeric association. Comparing telomere length of giant cell tumours to this of leukocytes of the same patient, a reduction has been demonstrated. Most commonly affected telomeres are 11p, 13p, 14p, 15p, 19q, 20q and 21p. 
